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Background
HIV-1 envelope protein gp41 is a very attractive vaccine
target as its epitopes are recognized by three broadly
neutralizing antibodies. However, the extreme hydro-
phobicity and very transient exposure of neutralizing
epitopes during infection has hampered its usage in
HIV-1 vaccine development. Our goal is to design a
soluble trimeric gp41 vaccine stabilized as a pre-hairpin
intermediate.
Methods
A gp41AVERY-minus recombinant was constructed,
which contained both gp41 ecto-domain and cyto-
domain, while the immunodominant AVERY region was
deleted to reduce elicitation of non-neutralizing antibo-
dies. Another protein, gp41-5M, was constructed by
introducing 5 point mutations to gp41AVERY-minus, at
the exposed hydrophobic residues of the trimeric coiled
coil region, in order to destabilize the interaction between
HR1 and HR2 helices and therefore mimic the gp41 pre-
hairpin intermediate. A ‘foldon’ structural tag was fused
at the C-terminus of gp41-5M to facilitate trimer forma-
tion, and phage T4 small outer capsid (Soc) protein was
fused at the N-terminus for arraying gp41 on T4 capsids.
The ability of purified Soc-gp41-5M proteins to inhibit
4E10 and 2F5 neutralizing activity was tested in the
TZM-bl assay. Immunization experiments were per-
formed in rabbits using soluble as well as T4 displayed
gp41 antigens to determine their immunogenicity.
Results
gp41 mutant proteins were over-expressed in E. coli and
purified in soluble form following denaturation, rena-
turation, and Histrap affinity chromatography. The Soc-
gp41-5M protein formed trimers and other oligomers,
and effectively competed with native epitopes present
on HIV-1 virus for binding to 4E10 and 2F5 antibodies
in the TZM-bl assay. The sera from all immunized rab-
bits showed binding antibodies to gp41 while some also
showed neutralizing antibodies.
Conclusion
Soluble near full-length trimeric gp41 immunogens can
be produced by interfering with the HR1-HR2 interac-
tions while retaining the 4E10 and 2F5 binding epitope
conformations. These proteins might be good vaccine
candidates to elicit broadly neutralizing antibodies.
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